Halozyme Inc. - HALO Net Assets per Single Share

Public company logo of Halozyme Therapeutics, Inc. (HALO)

The non-cyclical royalty model of Halozyme Therapeutics (HALO) ensures resilience against macro shocks, as evidenced by the book value per common share, where the latest value is recorded as 1.27. An environmental development vector reduces medical waste, optimizing the impact of chemistry on the environment. Stable demand from pharma behemoths for the licensing of subcutaneous drug delivery ensures the continuous expansion of sales markets.

Halozyme Therapeutics, Inc. (HALO) - Accounting Value per Share from 07/04/2022 to 10/29/2026

Summary analytical data breakdowns for halozyme.com (HALO)

- price and consensus price forecast:
Price Chart Halozyme Inc.|HALO - Price Target Chart
- market capitalization data:
Market Value Halozyme Therapeutics, Inc.|HALO - Total Enterprise Value
- book capitalization data:
Book Value per Share Halozyme|HALO - Company Net Assets|Market Capitalization to Book Value Ratio halozyme.com|HALO - Company Total Assets
- debt and liquidity data:
Debt to Equity Halozyme Therapeutics|HALO - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Halozyme|HALO - Company Total Debt|Debts to Book Capitalization Halozyme Therapeutics, Inc.|HALO - Long-Term Debt|Company Short-Term Debt Halozyme
Analysis of all company metrics:Halozyme Inc., HALO
Manufactured product of halozyme.com

Book value per share represents the portion of equity attributable to a single security. By analyzing the book value per share under RAS, an investor observes the trend of net assets minus liabilities. Growth in this metric depends on retained earnings and the volume of share buybacks. For Halozyme Therapeutics (HALO), this indicator reflects the efficiency of capitalizing royalties from partners. The stability of the chart confirms the reliability of patent protection and the success of clinical trials.

Competitor analysis for Halozyme Therapeutics

ONC - Net Assets per Single Share|RVMD: Net Assets per Single Share|Net Assets per Single Share AAPG|cgoncology.com (CGON) - Net Asset Value per Share|Book Value per Share URGN|Accounting Value per Share Bicara Therapeutics Inc|Book Value per Share PSNL|Book Value per Share ERAS (Erasca Oncology)|DCTH - Net Assets per Single Share|Equity per Share ymabs.com YMAB|AURA: Book Value per Share|CADL - Accounting Value per Share|Book Value per Share ARAY|SLS (SELLAS Life Sciences Group) - Net Asset Value per Share|ACTU - Net Assets per Single Share|Accounting Value of a Share citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Accounting Value per Share|Accounting Value of a Share Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Book Value per Share|WHWK - Accounting Value per Share|TScan - Accounting Value per Share|CSBR: Book Value per Share|Net Assets per Single Share xbiotech.com XBIT|CEL-SCI (CVM) - Accounting Value of a Share|Book Value per Share OSTX (OS Therapies Inc)|Net Asset Value per Share radiopharmtheranostics.com|Artiva Biotherapeutics, Inc. (ARTV) - Book Value per Share|Accounting Value of a Share adlainortye.com (ANL)|Book Value per Share VERU (Veru)|Tempest Therapeutics Inc - Book Value per Share|XLO - Net Assets per Single Share|RENB: Net Assets per Single Share|Net Assets per Single Share MURA|Net Asset Value per Share Kairos Pharma|Accounting Value per Share OnKure Therapeutics, Inc. OKUR|Share Book Value CytoMed (GDTC)|Curis, Inc. - Accounting Value per Share|Net Asset Value per Share APLM (apollomicsinc.com)|Tharimmune, Inc. - Net Assets per Single Share|Accounting Value per Share Advanced Biomed Inc. ADVB|GNPX (Genprex) - Book Value per Share|Calidi Biotherapeutics (CLDI) - Net Asset Value per Share|Accounting Value per Share Sunshine Biopharma, Inc. SBFM|Accounting Value of a Share Xenetic Biosciences, Inc.|Salarius Pharmaceuticals (SLRX) - Accounting Value per Share|Book Price of a Share purple-biotech.com|American Oncology Network (AONC) - Book Value per Share|Accounting Value of a Share BeiGene Ltd. (BGNE)|CKPT: Book Value per Share|elevationoncology.com - Net Asset Value per Share|Net Assets per Single Share iCAD Corp (ICAD)|IKNA - Accounting Value of a Share|NTBL: Book Value per Share|VIRX (Viracta Therapeutics, Inc.) - Book Value per Share|Net Assets per Single Share MorphoSys Corp MOR|Share Book Value NAYA Biosciences Corp|Ascentage Pharma Group - Book Value per Share